查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529774

結合疫苗市場規模、佔有率、趨勢分析報告：按產品、品牌、疾病、病原體、患者、地區、細分市場預測，2024-2030年

Conjugate Vaccine Market Size, Share & Trends Analysis Report By Product (Monovalent, Multivalent), By Brand (Prevnar, CAPVAXIVE), By Disease, By Pathogen, By Patient, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

結合疫苗市場規模及趨勢

預計2023年全球結合疫苗市場規模為190.1億美元，預估2024年至2030年複合年成長率為9.60%。全球感染疾病率的上升是推動結合疫苗市場成長的主要因素。結合疫苗有助於預防多種嚴重的細菌性疾病，包括 b 型流感嗜血桿菌 (Hib)、肺炎鏈球菌感染和病菌感染。根據疾病預防控制中心的說法，肺炎球菌，特別是肺炎球菌，是美國細菌性腦膜炎的重要原因，凸顯了這種細菌造成的重大健康負擔。隨著感染疾病威脅公眾健康，對有效疫苗接種策略的需求不斷增加，從而推動了對結合疫苗的需求。

推動結合疫苗市場的另一個關鍵因素是新結合疫苗產品的監管核准數量不斷增加。核准數量的增加擴大了市場並促進了行業內的創新。公司正在鼓勵開發新型結合疫苗，以滿足未滿足的醫療需求並針對新出現的感染疾病。例如，2024年6月，美國FDA核准了CAPVAXIVE，一種成人肺炎球菌21價結合疫苗，用於預防侵襲性肺炎鏈球菌感染和肺炎鏈球菌感染。這項核准標誌著對抗肺炎鏈球菌感染的一個重要里程碑。肺炎鏈球菌感染可導致嚴重的健康問題甚至死亡，尤其是老年人和患有某些健康問題的人等高風險族群。

世界各地的政府措施和免疫計畫正在對結合疫苗市場的成長產生重大影響。例如，世衛組織建議將肺炎鏈球菌結合疫苗（PCV）納入全球兒童免疫規劃。特別是兒童死亡率較高的國家，例如五歲以下兒童死亡率超過每 1,000 名活產嬰兒 50 人，應優先引進這些多成分 PCV。

個人和醫療保健專業人員對預防性健康實踐的日益重視，增加了對可提供長期預防感染疾病的疫苗的需求。能夠增強免疫反應的聯合疫苗適合這種預防醫學方法。

聯合疫苗的全球市場報告細分

該報告預測了2018年至2030年全球、區域和國家層面的收益成長，並對每個子區隔的最新行業趨勢進行了分析。為了本研究的目的，Grand View Research, Inc. 根據產品、品牌、疾病、病原體、患者和地區對全球結合疫苗市場報告進行了細分。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章結合疫苗市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/補充市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 結合疫苗市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章結合疫苗市場：產品、估計與趨勢分析

  • 2023年及2030年產品市場佔有率
  • 細分儀表板
  • 按產品分類的全球結合疫苗市場前景
  • 2018-2030年市場規模、預測及趨勢分析

第5章結合疫苗市場：品牌、估計與趨勢分析

  • 2023年及2030年品牌市場佔有率
  • 細分儀表板
  • 全球結合疫苗品牌市場前景
  • 2018-2030年市場規模、預測及趨勢分析

第6章結合疫苗市場：疾病、估計與趨勢分析

  • 2023年及2030年疾病市場佔有率
  • 細分儀表板
  • 按疾病分類的全球結合疫苗市場前景
  • 2018-2030年市場規模、預測及趨勢分析

第7章結合疫苗市場：病原體、估計和趨勢分析

  • 2023年及2030年病原體市場佔有率
  • 細分儀表板
  • 按病原體分類的全球結合疫苗市場前景
  • 2018-2030年市場規模、預測及趨勢分析

第8章結合疫苗市場：病人、估計和趨勢分析

  • 2023年及2030年患者市場佔有率
  • 細分儀表板
  • 按患者分類的全球結合疫苗市場前景
  • 2018-2030年市場規模、預測及趨勢分析

第9章結合疫苗市場：區域、估計和趨勢分析

  • 2023 年及 2030 年按地區分類的市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 2023年主要企業市場佔有率分析
    • Bavarian Nordic
    • Bharat Biotech
    • Biological E. Ltd.
    • Bio-Med
    • CSL Limited
    • GSK plc
    • GSPBL
    • Merck &Co., Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi
    • Serum Institute of India Pvt. Ltd.
    • Taj Pharmaceuticals Ltd.
Product Code: GVR-4-68040-349-3

Conjugate Vaccine Market Size & Trends

The global conjugate vaccine market size was estimated at USD 19.01 billion in 2023 and is expected to grow at a CAGR of 9.60% from 2024 to 2030. The rising incidence of infectious diseases globally is a significant driver for the growth of the conjugate vaccines market. Conjugate vaccines help protect against several serious bacterial diseases, including Haemophilus influenzae disease b (Hib, Pneumococcal infections, and Meningococcal infections. According to the CDC, pneumococci, specifically Streptococcus pneumonia bacteria, are a significant cause of bacterial meningitis in the U.S. highlighted the significant health burden posed by this bacterium. As infectious diseases threaten public health, there is a growing need for effective vaccination strategies, driving the demand for conjugate vaccines.

Another crucial factor driving the conjugate vaccines market is the rising regulatory approvals for new conjugate vaccine products. The increasing number of regulatory approvals expands the market and drives innovation within the industry. Companies are encouraged to develop novel conjugate vaccines to address unmet medical needs and target emerging infectious diseases. For Instance, in June 2024, the U.S. FDA approved CAPVAXIVE, a pneumococcal 21-valent conjugate vaccine for adults, to prevent invasive and pneumococcal disease. This approval marks a significant milestone in the fight against pneumococcal infections, which can lead to serious health issues and even death, especially among high-risk groups such as the elderly and those with specific pre-existing health problems.

Governmental initiatives and immunization programs worldwide have significantly influenced the growth of the conjugate vaccines market. For Instance, the WHO recommended including Pneumococcal Conjugate Vaccines (PCVs) in childhood immunization programs globally. Specifically, countries with high rates of childhood mortality, such as an under-5 mortality rate exceeding 50 deaths per 1000 births, should prioritize the introduction of these multicomponent PCVs.

Increasing emphasis on preventive healthcare practices among individuals and healthcare providers drives the demand for vaccines that offer long-term protection against infectious diseases. Conjugate vaccines, with their ability to enhance immune responses, align well with this preventive healthcare approach.

Global Conjugate Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global conjugate vaccine market report on the basis of product, brand, disease, pathogen, patient, and region

  • Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Monovalent Conjugate Vaccine
  • Multivalent Conjugate Vaccine
  • Brand Outlook (Revenue, USD Million, 2018 - 2030)
  • Prevnar
  • Synflorix
  • PedvaxHIB
  • Hiberix
  • ACT-HIB
  • Pentacel
  • Menveo
  • Menactra
  • MenQuadfi
  • VAXNEUVANCE
  • CAPVAXIVE
  • Others
  • Disease Outlook (Revenue, USD Million, 2018 - 2030)
  • Pneumococcal
  • Influenza
  • DTP
  • Meningococcal
  • Typhoid
  • Pathogen Outlook (Revenue, USD Million, 2018 - 2030)
  • Bacterial
  • Viral
  • Combination
  • Patient Outlook (Revenue, USD Million, 2018 - 2030)
  • Pediatric
  • Adults
  • Regional Outlook (Revenue in USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

  • Latin America

Brazil

Argentina

  • Middle East and Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Brand
    • 1.2.3. Disease
    • 1.2.4. Pathogen
    • 1.2.5. Patient
    • 1.2.6. Regional scope
    • 1.2.7. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Brand outlook
    • 2.2.3. Disease outlook
    • 2.2.4. Pathogen outlook
    • 2.2.5. Patient outlook
    • 2.2.6. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Conjugate Vaccines Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of infectious disease
      • 3.2.1.2. Regulatory Approvals
      • 3.2.1.3. Government Initiatives and Immunization Programs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost of Conjugate Vaccine
      • 3.2.2.2. Stringent Regulatory Requirements
  • 3.3. Conjugate Vaccines Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Conjugate Vaccines Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Conjugate Vaccines Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Monovalent Conjugate Vaccine
      • 4.4.1.1. Monovalent conjugate vaccine market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Multivalent Conjugate Vaccine

4.4.1.2.1. Multivalent conjugate vaccine market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Conjugate Vaccines Market: Brand Estimates & Trend Analysis

  • 5.1. Brand Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Conjugate Vaccines Market by Brand Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Prevnar
      • 5.4.1.1. Prevnar market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Synflorix
      • 5.4.2.1. Synflorix market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. PedvaxHIB
      • 5.4.3.1. PedvaxHIB market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Hiberix
      • 5.4.4.1. Hiberix market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. ACT-HIB
      • 5.4.5.1. ACT-HIB market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. Pentacel
      • 5.4.6.1. Pentacel market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.7. Menveo
      • 5.4.7.1. Menveo market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.8. Menactra
      • 5.4.8.1. Menactra market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.9. MenQuadfi
      • 5.4.9.1. MenQuadfi market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.10. VAXNEUVANCE
      • 5.4.10.1. VAXNEUVANCE market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.11. CAPVAXIVE
      • 5.4.11.1. CAPVAXIVE market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.12. Others
      • 5.4.12.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Conjugate Vaccines Market: Disease Estimates & Trend Analysis

  • 6.1. Disease Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Conjugate Vaccines Market by Disease Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Pneumococcal
      • 6.4.1.1. Pneumococcal market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Influenza
      • 6.4.2.1. Influenza market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. DTP
      • 6.4.3.1. DTP market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Meningococcal
      • 6.4.4.1. Meningococcal market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Typhoid
      • 6.4.5.1. Typhoid market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Conjugate Vaccines Market: Pathogen Estimates & Trend Analysis

  • 7.1. Pathogen Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Conjugate Vaccines Market by Pathogen Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Bacterial
      • 7.4.1.1. Bacterial Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Viral
      • 7.4.2.1. Viral market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Combination
      • 7.4.3.1. Combination market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Conjugate Vaccines Market: Patient Estimates & Trend Analysis

  • 8.1. Patient Market Share, 2023 & 2030
  • 8.2. Segment Dashboard
  • 8.3. Global Conjugate Vaccines Market by Patient Outlook
  • 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 8.4.1. Pediatric
      • 8.4.1.1. Pediatric Market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Adults
      • 8.4.2.1. Adults market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Conjugate Vaccines Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2023 & 2030
  • 9.2. Regional Market Dashboard
  • 9.3. Global Regional Market Snapshot
  • 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 9.5. North America
    • 9.5.1. North America
    • 9.5.2. U.S.
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Regulatory framework
      • 9.5.2.3. Competitive scenario
      • 9.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.3. Canada
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Regulatory framework
      • 9.5.3.3. Competitive scenario
      • 9.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.4. Mexico
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Regulatory framework
      • 9.5.4.3. Competitive scenario
      • 9.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6. Europe
    • 9.6.1. Europe
    • 9.6.2. UK
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Regulatory framework/ Reimbursement
      • 9.6.2.3. Competitive scenario
      • 9.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.3. Germany
      • 9.6.3.1. Key country dynamics
      • 9.6.3.2. Regulatory framework/ Reimbursement
      • 9.6.3.3. Competitive scenario
      • 9.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.4. France
      • 9.6.4.1. Key country dynamics
      • 9.6.4.2. Regulatory framework/ Reimbursement
      • 9.6.4.3. Competitive scenario
      • 9.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.5. Italy
      • 9.6.5.1. Key country dynamics
      • 9.6.5.2. Regulatory framework/ Reimbursement
      • 9.6.5.3. Competitive scenario
      • 9.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.6. Spain
      • 9.6.6.1. Key country dynamics
      • 9.6.6.2. Regulatory framework
      • 9.6.6.3. Competitive scenario
      • 9.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.7. Denmark
      • 9.6.7.1. Key country dynamics
      • 9.6.7.2. Regulatory framework/ Reimbursement
      • 9.6.7.3. Competitive scenario
      • 9.6.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.8. Sweden
      • 9.6.8.1. Key country dynamics
      • 9.6.8.2. Regulatory framework
      • 9.6.8.3. Competitive scenario
      • 9.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.9. Norway
      • 9.6.9.1. Key country dynamics
      • 9.6.9.2. Regulatory framework
      • 9.6.9.3. Competitive scenario
      • 9.6.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7. Asia Pacific
    • 9.7.1. Asia Pacific
    • 9.7.2. Japan
      • 9.7.2.1. Key country dynamics
      • 9.7.2.2. Regulatory framework/ Reimbursement
      • 9.7.2.3. Competitive scenario
      • 9.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.3. China
      • 9.7.3.1. Key country dynamics
      • 9.7.3.2. Regulatory framework/ Reimbursement
      • 9.7.3.3. Competitive scenario
      • 9.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.4. India
      • 9.7.4.1. Key country dynamics
      • 9.7.4.2. Regulatory framework/ Reimbursement
      • 9.7.4.3. Competitive scenario
      • 9.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.5. Australia
      • 9.7.5.1. Key country dynamics
      • 9.7.5.2. Regulatory framework/ Reimbursement
      • 9.7.5.3. Competitive scenario
      • 9.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.6. South Korea
      • 9.7.6.1. Key country dynamics
      • 9.7.6.2. Regulatory framework/ Reimbursement
      • 9.7.6.3. Competitive scenario
      • 9.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.7. Thailand
      • 9.7.7.1. Key country dynamics
      • 9.7.7.2. Regulatory framework/ Reimbursement
      • 9.7.7.3. Competitive scenario
      • 9.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8. Latin America
    • 9.8.1. Latin America
    • 9.8.2. Brazil
      • 9.8.2.1. Key country dynamics
      • 9.8.2.2. Regulatory framework
      • 9.8.2.3. Competitive scenario
      • 9.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.8.3. Argentina
      • 9.8.3.1. Key country dynamics
      • 9.8.3.2. Regulatory framework/ Reimbursement
      • 9.8.3.3. Competitive scenario
      • 9.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9. MEA
    • 9.9.1. MEA
    • 9.9.2. South Africa
      • 9.9.2.1. Key country dynamics
      • 9.9.2.2. Regulatory framework/ Reimbursement
      • 9.9.2.3. Competitive scenario
      • 9.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.9.3. Saudi Arabia
      • 9.9.3.1. Key country dynamics
      • 9.9.3.2. Regulatory framework/ Reimbursement
      • 9.9.3.3. Competitive scenario
      • 9.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.9.4. UAE
      • 9.9.4.1. Key country dynamics
      • 9.9.4.2. Regulatory framework/ Reimbursement
      • 9.9.4.3. Competitive scenario
      • 9.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.9.5. Kuwait
      • 9.9.5.1. Key country dynamics
      • 9.9.5.2. Regulatory framework
      • 9.9.5.3. Competitive scenario
      • 9.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company/Competition Categorization
  • 10.3. Vendor Landscape
    • 10.3.1. List of key distributors and channel partners
    • 10.3.2. Key customers
    • 10.3.3. Key company market share analysis, 2023
    • 10.3.4. Bavarian Nordic
      • 10.3.4.1. Company overview
      • 10.3.4.2. Financial performance
      • 10.3.4.3. Others benchmarking
      • 10.3.4.4. Strategic initiatives
    • 10.3.5. Bharat Biotech
      • 10.3.5.1. Company overview
      • 10.3.5.2. Financial performance
      • 10.3.5.3. Others benchmarking
      • 10.3.5.4. Strategic initiatives
    • 10.3.6. Biological E. Ltd.
      • 10.3.6.1. Company overview
      • 10.3.6.2. Financial performance
      • 10.3.6.3. Others benchmarking
      • 10.3.6.4. Strategic initiatives
    • 10.3.7. Bio-Med
      • 10.3.7.1. Company overview
      • 10.3.7.2. Financial performance
      • 10.3.7.3. Others benchmarking
      • 10.3.7.4. Strategic initiatives
    • 10.3.8. CSL Limited
      • 10.3.8.1. Company overview
      • 10.3.8.2. Financial performance
      • 10.3.8.3. Others benchmarking
      • 10.3.8.4. Strategic initiatives
    • 10.3.9. GSK plc
      • 10.3.9.1. Company overview
      • 10.3.9.2. Financial performance
      • 10.3.9.3. Others benchmarking
      • 10.3.9.4. Strategic initiatives
    • 10.3.10. GSPBL
      • 10.3.10.1. Company overview
      • 10.3.10.2. Financial performance
      • 10.3.10.3. Others benchmarking
      • 10.3.10.4. Strategic initiatives
    • 10.3.11. Merck & Co., Inc.
      • 10.3.11.1. Company overview
      • 10.3.11.2. Financial performance
      • 10.3.11.3. Others benchmarking
      • 10.3.11.4. Strategic initiatives
    • 10.3.12. Novartis AG
      • 10.3.12.1. Company overview
      • 10.3.12.2. Financial performance
      • 10.3.12.3. Others benchmarking
      • 10.3.12.4. Strategic initiatives
    • 10.3.13. Pfizer, Inc.
      • 10.3.13.1. Company overview
      • 10.3.13.2. Financial performance
      • 10.3.13.3. Others benchmarking
      • 10.3.13.4. Strategic initiatives
    • 10.3.14. Sanofi
      • 10.3.14.1. Company overview
      • 10.3.14.2. Financial performance
      • 10.3.14.3. Others benchmarking
      • 10.3.14.4. Strategic initiatives
    • 10.3.15. Serum Institute of India Pvt. Ltd.
      • 10.3.15.1. Company overview
      • 10.3.15.2. Financial performance
      • 10.3.15.3. Others benchmarking
      • 10.3.15.4. Strategic initiatives
    • 10.3.16. Taj Pharmaceuticals Ltd.
      • 10.3.16.1. Company overview
      • 10.3.16.2. Financial performance
      • 10.3.16.3. Others benchmarking
      • 10.3.16.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America conjugate vaccines market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 5 North America conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 6 North America conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 7 North America conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 8 U.S. conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 9 U.S. conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 10 U.S. conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 11 U.S. conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 12 U.S. conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 13 Canada conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 14 Canada conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 15 Canada conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 16 Canada conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 17 Canada conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 18 Mexico conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 19 Mexico conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 20 Mexico conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 21 Mexico conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 22 Mexico conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 23 Europe conjugate vaccines market, by region, 2018 - 2030 (USD Million)
  • Table 24 Europe conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 25 Europe conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 26 Europe conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 27 Europe conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 28 Europe conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 29 Germany conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 30 Germany conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 31 Germany conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 32 Germany conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 33 Germany conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 34 UK conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 35 UK conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 36 UK conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 37 UK conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 38 UK conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 39 France conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 40 France conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 41 France conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 42 France conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 43 France conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 44 Italy conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 45 Italy conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 46 Italy conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 47 Italy conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 48 Italy conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 49 Spain conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 50 Spain conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 51 Spain conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 52 Spain conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 53 Spain conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 54 Denmark conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 55 Denmark conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 56 Denmark conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 57 Denmark conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 58 Denmark conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 59 Sweden conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 60 Sweden conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 61 Sweden conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 62 Sweden conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 63 Sweden conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 64 Norway conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 65 Norway conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 66 Norway conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 67 Norway conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 68 Norway conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 69 Asia Pacific conjugate vaccines market, by region, 2018 - 2030 (USD Million)
  • Table 70 Asia Pacific conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 71 Asia Pacific conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 72 Asia Pacific conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 74 Asia Pacific conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 75 China conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 76 China conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 77 China conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 78 China conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 79 China conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 80 Japan conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 81 Japan conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 82 Japan conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 83 Japan conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 84 Japan conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 85 India conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 86 India conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 87 India conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 88 India conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 89 India conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 90 South Korea conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 91 South Korea conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 92 South Korea conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 93 South Korea conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 94 South Korea conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 95 Australia conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 96 Australia conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 97 Australia conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 98 Australia conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 99 Australia conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 100 Thailand conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 101 Thailand conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 102 Thailand conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 103 Thailand conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 104 Thailand conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 105 Latin America conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 106 Latin America conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 107 Latin America conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 108 Latin America conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 109 Latin America conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 110 Brazil conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 111 Brazil conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 112 Brazil conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 113 Brazil conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 114 Brazil conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 115 Argentina conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 116 Argentina conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 117 Argentina conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 118 Argentina conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 119 Argentina conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 120 MEA conjugate vaccines market, by region, 2018 - 2030 (USD Million)
  • Table 121 MEA conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 122 MEA conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 123 MEA conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 124 MEA conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 125 MEA conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 126 South Africa conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 127 South Africa conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 128 South Africa conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 129 South Africa conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 130 South Africa conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 131 Saudi Arabia conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 132 Saudi Arabia conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 133 Saudi Arabia conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 134 Saudi Arabia conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 135 Saudi Arabia conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 136 UAE conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 137 UAE conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 138 UAE conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 139 UAE conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 140 UAE conjugate vaccines market, by patient, 2018 - 2030 (USD Million)
  • Table 141 Kuwait conjugate vaccines market, by product, 2018 - 2030 (USD Million)
  • Table 142 Kuwait conjugate vaccines market, by brand, 2018 - 2030 (USD Million)
  • Table 143 Kuwait conjugate vaccines market, by disease, 2018 - 2030 (USD Million)
  • Table 144 Kuwait conjugate vaccines market, by pathogen, 2018 - 2030 (USD Million)
  • Table 145 Kuwait conjugate vaccines market, by patient, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Conjugate Vaccines market: market outlook
  • Fig. 14 Conjugate vaccines competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Conjugate vaccines market driver impact
  • Fig. 20 Conjugate vaccines market restraint impact
  • Fig. 21 Conjugate vaccines market strategic initiatives analysis
  • Fig. 22 Conjugate vaccines market: Product movement analysis
  • Fig. 23 Conjugate vaccines market: Product outlook and key takeaways
  • Fig. 24 Influenza conjugate vaccine market estimates and forecast, 2018 - 2030
  • Fig. 25 Multivalent conjugate vaccine market estimates and forecast, 2018 - 2030
  • Fig. 26 Conjugate vaccines market: Brand movement analysis
  • Fig. 27 Conjugate vaccines market: Brand outlook and key takeaways
  • Fig. 28 Prevnar market estimates and forecast, 2018 - 2030
  • Fig. 29 Synflorix market estimates and forecast, 2018 - 2030
  • Fig. 30 PedvaxHIB market estimates and forecast, 2018 - 2030
  • Fig. 31 Hiberix market estimates and forecast, 2018 - 2030
  • Fig. 32 ACT-HIB market estimates and forecast, 2018 - 2030
  • Fig. 33 Pentacelmarket estimates and forecast, 2018 - 2030
  • Fig. 34 Menveo market estimates and forecast, 2018 - 2030
  • Fig. 35 Menactra market estimates and forecast, 2018 - 2030
  • Fig. 36 MenQuadfi market estimates and forecast, 2018 - 2030
  • Fig. 37 VAXNEUVANCE estimates and forecast, 2018 - 2030
  • Fig. 38 CAPVAXIVE market estimates and forecast, 2018 - 2030
  • Fig. 39 Others market estimates and forecast, 2018 - 2030
  • Fig. 40 Conjugate vaccines Market: Disease movement analysis
  • Fig. 41 Conjugate vaccines market: Disease outlook and key takeaways
  • Fig. 42 Pneumococcal market estimates and forecasts, 2018 - 2030
  • Fig. 43 Influenza market estimates and forecasts, 2018 - 2030
  • Fig. 44 DTP market estimates and forecasts, 2018 - 2030
  • Fig. 45 Meningococcal market estimates and forecasts, 2018 - 2030
  • Fig. 46 Typhoid market estimates and forecasts, 2018 - 2030
  • Fig. 47 Conjugate vaccines market: Pathogen movement analysis
  • Fig. 48 Conjugate vaccines market: Pathogen outlook and key takeaways
  • Fig. 49 Bacterial market estimates and forecast, 2018 - 2030
  • Fig. 50 Viral market estimates and forecast, 2018 - 2030
  • Fig. 51 Combination market estimates and forecast, 2018 - 2030
  • Fig. 52 Conjugate vaccines market: Patient movement analysis
  • Fig. 53 Conjugate vaccines market: Patient outlook and key takeaways
  • Fig. 54 Pediatric market estimates and forecasts,2018 - 2030
  • Fig. 55 Adults market estimates and forecasts,2018 - 2030
  • Fig. 56 Global Conjugate vaccines market: Regional movement analysis
  • Fig. 57 Global Conjugate vaccines market: Regional outlook and key takeaways
  • Fig. 58 Global Conjugate vaccines market share and leading players
  • Fig. 59 North America market share and leading players
  • Fig. 60 Europe market share and leading players
  • Fig. 61 Asia Pacific market share and leading players
  • Fig. 62 Latin America market share and leading players
  • Fig. 63 Middle East & Africa market share and leading players
  • Fig. 64 North America, by country
  • Fig. 65 North America
  • Fig. 66 North America market estimates and forecasts, 2018 - 2030
  • Fig. 67 U.S. key country dynamics
  • Fig. 68 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 69 Canada key country dynamics
  • Fig. 70 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 71 Mexico key country dynamics
  • Fig. 72 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 73 Europe
  • Fig. 74 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 75 UK key country dynamics
  • Fig. 76 UK market estimates and forecasts, 2018 - 2030
  • Fig. 77 Germany key country dynamics
  • Fig. 78 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 79 France key country dynamics
  • Fig. 80 France market estimates and forecasts, 2018 - 2030
  • Fig. 81 Italy key country dynamics
  • Fig. 82 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 83 Spain key country dynamics
  • Fig. 84 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 85 Denmark key country dynamics
  • Fig. 86 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 87 Sweden key country dynamics
  • Fig. 88 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 89 Norway key country dynamics
  • Fig. 90 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 91 Asia Pacific
  • Fig. 92 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 93 China key country dynamics
  • Fig. 94 China market estimates and forecasts, 2018 - 2030
  • Fig. 95 Japan key country dynamics
  • Fig. 96 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 97 India key country dynamics
  • Fig. 98 India market estimates and forecasts, 2018 - 2030
  • Fig. 99 Australia key country dynamics
  • Fig. 100 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 101 South Korea key country dynamics
  • Fig. 102 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 103 Thailand key country dynamics
  • Fig. 104 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 105 Latin America
  • Fig. 106 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 107 Brazil key country dynamics
  • Fig. 108 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 109 Argentina key country dynamics
  • Fig. 110 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 111 Middle East and Africa
  • Fig. 112 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 113 South Africa key country dynamics
  • Fig. 114 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 115 Saudi Arabia key country dynamics
  • Fig. 116 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 117 UAE key country dynamics
  • Fig. 118 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 119 Kuwait key country dynamics
  • Fig. 120 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 121 Market share of key market players - Conjugate vaccines market